Lupus Research Alliance Response to Janssen’s Ustekinumab Lupus Trial Discontinuation
June 26, 2020
The Lupus Research Alliance is disappointed at news from Janssen Pharmaceutical Companies of Johnson & Johnson that...
Stelara
Breadth of Clinical Research Presented at the 2019 ACR/ARP Annual Meeting Brings Hope for New Lupus Treatments
November 14, 2019
The Lupus Research Alliance staff was on the ground at the 2019 ACR/ARP Annual Meeting and highly...
Study Shows Need for Greater Awareness of Biologics for Lupus
August 19, 2019
A new study led by Dr. S. Sam Lim of Emory University found a need for more...
Stelara® Effective Over One Year and Reduces Severe Flares
Results of two analyses from a Phase 2 study of Stelara® (ustekinumab) in lupus showed the drug’s effectiveness over...
Updates in Lupus Clinical Research from the LUPUS 2019 Meeting
April 11, 2019
The Lupus Research Alliance is pleased to share the results from four clinical trials presented at LUPUS...
Stelara® and Olumiant® Considered Promising by Lupus Expert
February 19, 2019
In Healio Rheumatology, Dr. Gregg Silverman, professor of medicine and pathology at NYU School of Medicine, provided...
Lupus Research Alliance and Lupus Therapeutics Partner on New Phase 3 Trial Testing Potential Benefit of Ustekinumab (Stelara®) in Lupus
The Lupus Research Alliance announced that clinical research affiliate Lupus Therapeutics is partnering with the pharmaceutical company, Janssen, to...
ACR|ARHP News on Potential New Lupus Treatments
October 25, 2018
The Lupus Research Alliance was on the ground at the American College of Rheumatology 2018 meeting to...
STELARA® Shows Positive Results
STELARA® (Ustekinumab)
Shows Positive Results in Treatment of Systemic Lupus Erythematosus in Phase 2 Trial
60 percent of patients receiving...
Lupus Research Alliance Prompted Stelara® Study for Lupus
NEW YORK, NY. November 6, 2017 -- Lupus Research Alliance welcomes compelling new data, presented at the American College...